Logo image of ISRG

INTUITIVE SURGICAL INC (ISRG) Stock Fundamental Analysis

USA - NASDAQ:ISRG - US46120E6023 - Common Stock

434.5 USD
+0.51 (+0.12%)
Last: 9/16/2025, 6:36:01 PM
434.21 USD
-0.29 (-0.07%)
After Hours: 9/16/2025, 6:36:01 PM
Fundamental Rating

7

ISRG gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 191 industry peers in the Health Care Equipment & Supplies industry. ISRG scores excellent points on both the profitability and health parts. This is a solid base for a good stock. ISRG is growing strongly while it is still valued neutral. This is a good combination! These ratings would make ISRG suitable for growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year ISRG was profitable.
In the past year ISRG had a positive cash flow from operations.
ISRG had positive earnings in each of the past 5 years.
ISRG had a positive operating cash flow in each of the past 5 years.
ISRG Yearly Net Income VS EBIT VS OCF VS FCFISRG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

1.2 Ratios

The Return On Assets of ISRG (12.93%) is better than 94.76% of its industry peers.
ISRG has a Return On Equity of 14.52%. This is amongst the best in the industry. ISRG outperforms 90.58% of its industry peers.
Looking at the Return On Invested Capital, with a value of 13.28%, ISRG belongs to the top of the industry, outperforming 93.72% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for ISRG is above the industry average of 8.46%.
The 3 year average ROIC (12.20%) for ISRG is below the current ROIC(13.28%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 12.93%
ROE 14.52%
ROIC 13.28%
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)12.2%
ROIC(5y)11.86%
ISRG Yearly ROA, ROE, ROICISRG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

ISRG has a better Profit Margin (28.51%) than 95.81% of its industry peers.
In the last couple of years the Profit Margin of ISRG has declined.
The Operating Margin of ISRG (28.93%) is better than 96.86% of its industry peers.
ISRG's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 66.61%, ISRG is in the better half of the industry, outperforming 71.73% of the companies in the same industry.
In the last couple of years the Gross Margin of ISRG has remained more or less at the same level.
Industry RankSector Rank
OM 28.93%
PM (TTM) 28.51%
GM 66.61%
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
ISRG Yearly Profit, Operating, Gross MarginsISRG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

7

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ISRG is still creating some value.
Compared to 1 year ago, ISRG has more shares outstanding
Compared to 5 years ago, ISRG has more shares outstanding
There is no outstanding debt for ISRG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ISRG Yearly Shares OutstandingISRG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
ISRG Yearly Total Debt VS Total AssetsISRG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

There is no outstanding debt for ISRG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.53
WACC8.69%
ISRG Yearly LT Debt VS Equity VS FCFISRG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.3 Liquidity

ISRG has a Current Ratio of 5.64. This indicates that ISRG is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.64, ISRG belongs to the top of the industry, outperforming 80.10% of the companies in the same industry.
ISRG has a Quick Ratio of 4.89. This indicates that ISRG is financially healthy and has no problem in meeting its short term obligations.
ISRG's Quick ratio of 4.89 is amongst the best of the industry. ISRG outperforms 81.68% of its industry peers.
Industry RankSector Rank
Current Ratio 5.64
Quick Ratio 4.89
ISRG Yearly Current Assets VS Current LiabilitesISRG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 26.97% over the past year.
The Earnings Per Share has been growing by 11.48% on average over the past years. This is quite good.
Looking at the last year, ISRG shows a very strong growth in Revenue. The Revenue has grown by 20.77%.
The Revenue has been growing by 13.27% on average over the past years. This is quite good.
EPS 1Y (TTM)26.97%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%23.03%
Revenue 1Y (TTM)20.77%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%21.4%

3.2 Future

ISRG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.53% yearly.
Based on estimates for the next years, ISRG will show a quite strong growth in Revenue. The Revenue will grow by 14.89% on average per year.
EPS Next Y13.56%
EPS Next 2Y13.58%
EPS Next 3Y14.55%
EPS Next 5Y14.53%
Revenue Next Year19.71%
Revenue Next 2Y17.08%
Revenue Next 3Y16.39%
Revenue Next 5Y14.89%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ISRG Yearly Revenue VS EstimatesISRG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5B 10B 15B 20B
ISRG Yearly EPS VS EstimatesISRG Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

ISRG is valuated quite expensively with a Price/Earnings ratio of 53.98.
ISRG's Price/Earnings ratio is a bit cheaper when compared to the industry. ISRG is cheaper than 67.54% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.20. ISRG is valued rather expensively when compared to this.
Based on the Price/Forward Earnings ratio of 45.95, the valuation of ISRG can be described as expensive.
ISRG's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. ISRG is cheaper than 69.11% of the companies in the same industry.
ISRG is valuated expensively when we compare the Price/Forward Earnings ratio to 22.71, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 53.98
Fwd PE 45.95
ISRG Price Earnings VS Forward Price EarningsISRG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ISRG is valued a bit cheaper than 68.06% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ISRG indicates a somewhat cheap valuation: ISRG is cheaper than 71.20% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 78.1
EV/EBITDA 45.34
ISRG Per share dataISRG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ISRG does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of ISRG may justify a higher PE ratio.
ISRG's earnings are expected to grow with 14.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.98
PEG (5Y)4.7
EPS Next 2Y13.58%
EPS Next 3Y14.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ISRG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTUITIVE SURGICAL INC

NASDAQ:ISRG (9/16/2025, 6:36:01 PM)

After market: 434.21 -0.29 (-0.07%)

434.5

+0.51 (+0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-22 2025-07-22/amc
Earnings (Next)10-15 2025-10-15/amc
Inst Owners88.73%
Inst Owner Change-5.32%
Ins Owners0.45%
Ins Owner Change1.39%
Market Cap155.76B
Analysts79
Price Target597.45 (37.5%)
Short Float %1.53%
Short Ratio2.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.33%
Min EPS beat(2)3.05%
Max EPS beat(2)11.61%
EPS beat(4)4
Avg EPS beat(4)11.45%
Min EPS beat(4)3.05%
Max EPS beat(4)20.76%
EPS beat(8)8
Avg EPS beat(8)8.83%
EPS beat(12)11
Avg EPS beat(12)6.4%
EPS beat(16)13
Avg EPS beat(16)4.58%
Revenue beat(2)2
Avg Revenue beat(2)1.47%
Min Revenue beat(2)1.09%
Max Revenue beat(2)1.84%
Revenue beat(4)3
Avg Revenue beat(4)1.98%
Min Revenue beat(4)-0.14%
Max Revenue beat(4)5.12%
Revenue beat(8)4
Avg Revenue beat(8)0.5%
Revenue beat(12)6
Avg Revenue beat(12)0.42%
Revenue beat(16)7
Avg Revenue beat(16)0.13%
PT rev (1m)-0.25%
PT rev (3m)0.68%
EPS NQ rev (1m)0.11%
EPS NQ rev (3m)2.12%
EPS NY rev (1m)4.08%
EPS NY rev (3m)4.34%
Revenue NQ rev (1m)0.08%
Revenue NQ rev (3m)0.82%
Revenue NY rev (1m)0.13%
Revenue NY rev (3m)1.38%
Valuation
Industry RankSector Rank
PE 53.98
Fwd PE 45.95
P/S 17.03
P/FCF 78.1
P/OCF 55.11
P/B 8.68
P/tB 8.85
EV/EBITDA 45.34
EPS(TTM)8.05
EY1.85%
EPS(NY)9.46
Fwd EY2.18%
FCF(TTM)5.56
FCFY1.28%
OCF(TTM)7.88
OCFY1.81%
SpS25.51
BVpS50.08
TBVpS49.11
PEG (NY)3.98
PEG (5Y)4.7
Profitability
Industry RankSector Rank
ROA 12.93%
ROE 14.52%
ROCE 14.74%
ROIC 13.28%
ROICexc 28.31%
ROICexgc 29.53%
OM 28.93%
PM (TTM) 28.51%
GM 66.61%
FCFM 21.81%
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)12.2%
ROIC(5y)11.86%
ROICexc(3y)18.44%
ROICexc(5y)19.03%
ROICexgc(3y)19.29%
ROICexgc(5y)20.12%
ROCE(3y)13.54%
ROCE(5y)13.16%
ROICexcg growth 3Y-7.59%
ROICexcg growth 5Y-7%
ROICexc growth 3Y-6.87%
ROICexc growth 5Y-6.06%
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
F-Score6
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 144.66%
Cap/Sales 9.1%
Interest Coverage 250
Cash Conversion 87.74%
Profit Quality 76.48%
Current Ratio 5.64
Quick Ratio 4.89
Altman-Z N/A
F-Score6
WACC8.69%
ROIC/WACC1.53
Cap/Depr(3y)197.35%
Cap/Depr(5y)162.98%
Cap/Sales(3y)12.27%
Cap/Sales(5y)10.16%
Profit Quality(3y)56.77%
Profit Quality(5y)75.99%
High Growth Momentum
Growth
EPS 1Y (TTM)26.97%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%23.03%
EPS Next Y13.56%
EPS Next 2Y13.58%
EPS Next 3Y14.55%
EPS Next 5Y14.53%
Revenue 1Y (TTM)20.77%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%21.4%
Revenue Next Year19.71%
Revenue Next 2Y17.08%
Revenue Next 3Y16.39%
Revenue Next 5Y14.89%
EBIT growth 1Y34.69%
EBIT growth 3Y8.76%
EBIT growth 5Y11.37%
EBIT Next Year40.01%
EBIT Next 3Y23.31%
EBIT Next 5Y20.2%
FCF growth 1Y69.15%
FCF growth 3Y-9.1%
FCF growth 5Y2.14%
OCF growth 1Y52.09%
OCF growth 3Y4.95%
OCF growth 5Y8.61%